Tags

Type your tag names separated by a space and hit enter

Experimental therapeutics of neurodegenerative disorders: unmet needs.

Abstract

Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Suite 212, 1351 Mt. Hope Avenue, Rochester, NY 14620, USA.

    Source

    Science (New York, N.Y.) 282:5391 1998 Nov 06 pg 1072-4

    MeSH

    Alzheimer Disease
    Animals
    Blood-Brain Barrier
    Clinical Trials as Topic
    Drug Evaluation, Preclinical
    Genetic Predisposition to Disease
    Hepatolenticular Degeneration
    Humans
    Huntington Disease
    Neurodegenerative Diseases
    Neuroprotective Agents
    Parkinson Disease

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Review

    Language

    eng

    PubMed ID

    9804537

    Citation

    Shoulson, I. "Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs." Science (New York, N.Y.), vol. 282, no. 5391, 1998, pp. 1072-4.
    Shoulson I. Experimental therapeutics of neurodegenerative disorders: unmet needs. Science. 1998;282(5391):1072-4.
    Shoulson, I. (1998). Experimental therapeutics of neurodegenerative disorders: unmet needs. Science (New York, N.Y.), 282(5391), pp. 1072-4.
    Shoulson I. Experimental Therapeutics of Neurodegenerative Disorders: Unmet Needs. Science. 1998 Nov 6;282(5391):1072-4. PubMed PMID: 9804537.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Experimental therapeutics of neurodegenerative disorders: unmet needs. A1 - Shoulson,I, PY - 1998/11/6/pubmed PY - 1998/11/6/medline PY - 1998/11/6/entrez SP - 1072 EP - 4 JF - Science (New York, N.Y.) JO - Science VL - 282 IS - 5391 N2 - Viewpoint The experimental therapeutics of neurodegenerative disorders is in its infancy, but neuroprotective strategies are already being applied in healthy persons at high risk of developing disease as well as in patients with manifest illness. Knowledge of etiology and pathogenesis, improved design of clinical trials, the development of biological markers, the advent of genetic animal models, the enhanced identification of susceptibility factors, and more effective drug delivery-such advances have improved the prospects for forestalling onset of illness and clinical decline in the growing numbers of people affected by neurodegenerative disorders. SN - 0036-8075 UR - https://www.unboundmedicine.com/medline/citation/9804537/Experimental_therapeutics_of_neurodegenerative_disorders:_unmet_needs_ L2 - http://www.sciencemag.org/cgi/pmidlookup?view=long&pmid=9804537 DB - PRIME DP - Unbound Medicine ER -